Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaceutical Manufacturers Association

Executive Summary

Asks FDA Commissioner Kessler in July 31 letter to "withdraw" the Center for Drug Evaluation and Research's proposed policy to allow agency approval of indications over sponsors' objections. PMA contended that the policy, set forth in a Jan. 15 memo and expected to be published this month in the Federal Register ("The Pink Sheet" Aug. 3, p. 7), may discourage sponsors from pursuing early development of what they consider minor indications for fear that the agency will approve the minor indications and "relegate" major indications to efficacy supplements, which are perceived as being approved more slowly.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS021316

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel